Pfizer posts 4Q loss, misses Street views, on lower revenue

Pfizer’s ongoing restructuring is significantly reducing revenue, resulting in a $337 million loss in its fourth quarter and a miss of Wall Street’s profit expectations.

The results and Pfizer’s 2020 financial forecasts didn’t please investors, who drove Pfizer shares down more than 4%, an unusually large drop for the biggest U.S. drugmaker. Pfizer also said results will be delayed until next year from a key study of whether its blockbuster Ibrance decreases chances of breast cancer recurring.

Pfizer executives, though, predicted a positive, if complicated, future as the company divests lower-profit segments to focus on its more lucrative new prescription drugs business.

“We finished 2019 with strong momentum and look forward to further momentum,” CEO Albert Borla told analysts on a conference call Tuesday. That includes what Borla called the company’s best-ever pipeline, thanks to paring its portfolio to focus on six disease areas where it has great expertise.

The maker of Xeljanz for rheumatoid arthritis and the Prevanr 13 vaccine against pneumonia and related infections reported a net loss of 6 cents per share, mainly due to shifting its consumer health business into a joint venture last year. In the year-earlier quarter, Pfizer lost $394 million, or 7 cents per share.

Adjusted earnings of $3.11 billion, or 55 cents per share, fell short of the 58 cents a share expected by analysts surveyed by FactSet.

Revenue totalled $12.69 billion in the October-December quarter. That topped the $12.61 billion that analysts were expecting, but was 9% lower than a year earlier. Sales in emerging markets like China and India jumped 14% to $3.24 billion.

UBS analyst Navin Jacob wrote to investors that three growth drivers — Ibrance, Xeljanz and Vyndaqel for a rare, fatal heart disorder — had lower-than-expected sales, and operating expenses were surprisingly high. That was mainly due to increased spending on marketing of newer drugs and testing of several future drugs.

In afternoon trading, Pfizer shares fell $2.02, or 5%, to $38.14, while the broader markets rose significantly.

Pfizer Biopharma, its innovative prescription drug business, posted quarterly revenue of $10.53 billion, led by Prevnar 13, Xeljanz, stroke preventer Eliquis and breast cancer pill Ibrance.

Its Upjohn business, which sells off-patent drugs such as Lipitor and Viagra, had revenue of $2.16 billion.

The New York-based company has been executing a major slim down to focus on developing new drugs.

Last July, Pfizer moved its huge stable of nonprescription medicines — including pain reliever Advil and Centrum vitamins — into a new joint venture with partner GlaxoSmithKline. Pfizer owns 32% of the JV, which brought Pfizer a profit of $129 million in the quarter. Meanwhile, Pfizer plans to combine its Upjohn business with generic drugmaker Mylan by mid-summer to create a new drugmaker called Viatris.

Pfizer noted it has three recently approved biosimilar drugs, near-copies of pricey biologic drugs “manufactured” in living cells, that have just launched or will by mid-February. The biosimilar versons of cancer drugs Herceptin, Avastin and Rituxan are being sold for nearly 25% below the brands’ list prices.

For all of 2019, Pfizer reported net income of $16.27 billion, or $2.87 per share. Revenue totalled $51.75 billion, down 4% from 2018’s revenue. It spent $8 billion on shareholder dividends and $8.9 billion on share repurchases during the year.

Pfizer said that this year it won’t buy back any shares, so it can plow that money into drug development.

Looking ahead, Pfizer Inc. forecast adjusted net income of $2.82 to $2.92 per share, on revenue of $48.5 billion to $50.5 billion for 2020.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Blockades remain in place as Wet’suwet’en hereditary chiefs returning to B.C.

Hereditary chiefs from Wet’suwet’en First Nation are expected to return to British… Continue reading

Fort Macleod, Alta., to get special advance screening of new ‘Ghostbusters’ film

There will be something strange in the neighbourhood of Fort Macleod, Alta.,… Continue reading

Hundreds turn up at Coldest Night of Year walk in Red Deer

It wasn’t the coldest night of the year, which probably helped the… Continue reading

Police in Saskatoon shoot two dogs that attacked man, then advanced on officers

SASKATOON — Police in Saskatoon say officers had to open fire at… Continue reading

13-year-old Maskwacis teen missing

Maskwacis RCMP are asking for public assistance to locate 13-year-old Rebecca Soosay.… Continue reading

Fashion Fridays: The 8 best quality online stores! Shop the ultimate sales

Kim XO, helps to keep you looking good on Fashion Fridays on the Black Press Media Network

Your community calendar

Feb. 19 A Liberation of Holland event is being held at the… Continue reading

Wranglers win wild Game 1 double OT thriller over Red Deer Vipers

The best-of-seven series continues Sunday in Sylvan Lake

Kings and Queens basketball triumph over Ambrose, keep playoff hopes alive

Guard Sandra Garica-Bernal sets new Queens all-time steals mark

Five things to watch for in the Canadian business world in the coming week

TORONTO — Five things to watch for in the Canadian business world… Continue reading

View of a longtime economist: Slower growth but no recession

WASHINGTON — In this high-profile election year, the U.S. economy boasts an… Continue reading

Amy, chasing: Klobuchar, already beating odds, faces uphill climb

WASHINGTON — It’s been a running gag ever since she launched her… Continue reading

B.C. money laundering inquiry to begin amid hopes for answers, accountability

VANCOUVER — British Columbia’s attorney general hopes an inquiry into money laundering… Continue reading

Russian spy case documents missing or destroyed, Canada’s info watchdog finds

OTTAWA — Federal officials lost or possibly destroyed sensitive records about the… Continue reading

Most Read